Pediatric Cancer Clinical Trial Finder
We believe that patients and families should have tools available to help make the search for treatments easier. For that reason, we’ve developed a Pediatric Cancer Clinical Trial Navigator for CAR T-cell therapy and other immunotherapy treatments. Use the filters to display relevant trials. Clicking on a card will allow you to access more detailed information, including contact information, for each clinical trial.
Region
Age Group
Condition
Therapy
Trial Phase
Trial Status
Genetic
Genetic Double Helix
Biological
Genetic Double Helix
Drug
Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia
U.S.
WA
Active, not recruiting
Learn More
Genetic
Genetic Double Helix
Biological
Drug
Genetic Double Helix
CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin’s Lymphoma, ALL & CLL
U.S.
TX
Active, not recruiting
Learn More
Genetic
Genetic Double Helix
Biological
Drug
Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells
U.S.
CA, GA, MD, NE, NJ, NY, TN, TX
Recruiting
Learn More
Genetic
Genetic Double Helix
Biological
Drug
Genetic Double Helix
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
U.S.
TX
Recruiting
Learn More
Genetic
Genetic Double Helix
Biological
Drug
Genetic Double Helix
T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
U.S.
MA, NY
Active, not recruiting
Learn More
Genetic
Biological
Genetic Double Helix
Drug
Genetic Double Helix
Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
U.S.
NC
Recruiting
Learn More
Genetic
Biological
Genetic Double Helix
Drug
Genetic Double Helix
Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
U.S.
TX
Active, not recruiting
Learn More
Genetic
Biological
Genetic Double Helix
Drug
Genetic Double Helix
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
U.S.
MD
Recruiting
Learn More
Genetic
Genetic Double Helix
Biological
Drug
Genetic Double Helix
In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
U.S.
NY
Recruiting
Learn More
Genetic
Genetic Double Helix
Biological
Drug
Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
U.S.
CA, MA
Other
Learn More
Genetic
Biological
Genetic Double Helix
Drug
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
U.S.
CA
Recruiting
Learn More
Genetic
Biological
Genetic Double Helix
Drug
Genetic Double Helix
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
U.S.
CA
Recruiting
Learn More

© 2014-2024 Emily Whitehead Foundation - Activate the Cure® for Childhood Cancer | All Rights Reserved

Privacy Policy